Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
22:38
A commercial ship caught fire in the Black Sea: The crew of 12 sailors was rescued by the authorities
22:20
Nicușor Dan, after the trilateral meeting in Chișinău: Romania, the Republic of Moldova, and Ukraine will continue collaboration in the fields of infrastructure, energy, and security.
22:01
Péter Magyar: Paks operates at maximum capacity / The nuclear power plant in Romania, previously cited as an example, has been shut down for two weeks.
21:38
UEFA has conducted the draw for the main stage of the Champions League / Liverpool and Real for Chivu
21:18
Explosion of a car in Saint Petersburg: A Russian army officer has died, and his wife has been injured.
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
